Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis

Conclusions
Serum ocrelizumab concentration was strongly associated with B-cell count. Measurement of ocrelizumab drug concentrations and ADAs could play an important role to further personalise treatment and predict the start of B-cell repopulation.

Source: Journal of Neurology, Neurosurgery and Psychiatry - May 15, 2023 Category: Neurosurgery Authors: Toorop, A. A., Hogenboom, L., Bloem, K., Kocyigit, M., Commandeur, N. W. M., Wijnants, A., Lissenberg-Witte, B. I., Strijbis, E. M. M., Uitdehaag, B. M. J., Rispens, T., Killestein, J., van Kempen, Z. L. E. Tags: Multiple sclerosis Source Type: research